Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments

Fig. 2

Exploration of the tumor microenvironment in KMT2-MUT and KMT2-WT tumors. A Comparison of the scores for 10 immunogenomic indicators between KMT2-MUT and KMT2-WT tumors. B The difference of mRNA expression levels in MHC molecules, coinhibitors, chemokines, receptors, and costimulators between KMT2-MUT and KMT2-WT tumors. C Two stable immune subtypes defined as “hot tumor” and “cold tumor” were identified using an unsupervised cluster. D A higher proportion of “hot tumors” was observed in tumors with KMT2 family mutations. E Differences in leukocyte fraction (DNA methylation algorithm), lymphocyte fraction (CIBERSORT algorithm), TIL fraction (molecular estimate), and the TIL regional fraction (H&E image estimate) between KMT2-MUT and KMT2-WT tumors. F The volcanic diagram provides a more in-depth presentation of higher immune signature scores in KMT2-MUT tumors. G Comparison of CD8 T cells fraction (CIBERSORT algorithm) between KMT2-MUT and KMT2-WT tumors. H Comparison of CYT between KMT2-WT and KMT2-MUT tumors. I Comparison of 29 immune signature scores estimated using the “ssGSEA” method between KMT2-MUT and KMT2-WT tumors

Back to article page

Molecular Cancer

ISSN: 1476-4598